Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 49

1.

Oncogenic NRAS, required for pathogenesis of embryonic rhabdomyosarcoma, relies upon the HMGA2-IGF2BP2 pathway.

Li Z, Zhang Y, Ramanujan K, Ma Y, Kirsch DG, Glass DJ.

Cancer Res. 2013 May 15;73(10):3041-50. doi: 10.1158/0008-5472.CAN-12-3947. Epub 2013 Mar 27.

2.

An HMGA2-IGF2BP2 axis regulates myoblast proliferation and myogenesis.

Li Z, Gilbert JA, Zhang Y, Zhang M, Qiu Q, Ramanujan K, Shavlakadze T, Eash JK, Scaramozza A, Goddeeris MM, Kirsch DG, Campbell KP, Brack AS, Glass DJ.

Dev Cell. 2012 Dec 11;23(6):1176-88. doi: 10.1016/j.devcel.2012.10.019. Epub 2012 Nov 21. Erratum in: Dev Cell. 2013 Jan 14;24(1):112.

3.

MEK/ERK inhibitor U0126 affects in vitro and in vivo growth of embryonal rhabdomyosarcoma.

Marampon F, Bossi G, Ciccarelli C, Di Rocco A, Sacchi A, Pestell RG, Zani BM.

Mol Cancer Ther. 2009 Mar;8(3):543-51. doi: 10.1158/1535-7163.MCT-08-0570. Epub 2009 Mar 3.

4.

Impaired Wnt signaling in embryonal rhabdomyosarcoma cells from p53/c-fos double mutant mice.

Singh S, Vinson C, Gurley CM, Nolen GT, Beggs ML, Nagarajan R, Wagner EF, Parham DM, Peterson CA.

Am J Pathol. 2010 Oct;177(4):2055-66. doi: 10.2353/ajpath.2010.091195. Epub 2010 Sep 9.

5.

Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo.

Posch C, Moslehi H, Feeney L, Green GA, Ebaee A, Feichtenschlager V, Chong K, Peng L, Dimon MT, Phillips T, Daud AI, McCalmont TH, LeBoit PE, Ortiz-Urda S.

Proc Natl Acad Sci U S A. 2013 Mar 5;110(10):4015-20. doi: 10.1073/pnas.1216013110. Epub 2013 Feb 19.

6.

Silencing of SPRY1 triggers complete regression of rhabdomyosarcoma tumors carrying a mutated RAS gene.

Schaaf G, Hamdi M, Zwijnenburg D, Lakeman A, Geerts D, Versteeg R, Kool M.

Cancer Res. 2010 Jan 15;70(2):762-71. doi: 10.1158/0008-5472.CAN-09-2532. Epub 2010 Jan 12.

7.

Simultaneous targeting of insulin-like growth factor-1 receptor and anaplastic lymphoma kinase in embryonal and alveolar rhabdomyosarcoma: a rational choice.

van Gaal JC, Roeffen MH, Flucke UE, van der Laak JA, van der Heijden G, de Bont ES, Suurmeijer AJ, Versleijen-Jonkers YM, van der Graaf WT.

Eur J Cancer. 2013 Nov;49(16):3462-70. doi: 10.1016/j.ejca.2013.06.022. Epub 2013 Jul 15.

PMID:
23867124
8.

Nras(G12D/+) promotes leukemogenesis by aberrantly regulating hematopoietic stem cell functions.

Wang J, Kong G, Liu Y, Du J, Chang YI, Tey SR, Zhang X, Ranheim EA, Saba-El-Leil MK, Meloche S, Damnernsawad A, Zhang J, Zhang J.

Blood. 2013 Jun 27;121(26):5203-7. doi: 10.1182/blood-2012-12-475863. Epub 2013 May 17.

9.

FGFR4 blockade exerts distinct antitumorigenic effects in human embryonal versus alveolar rhabdomyosarcoma.

Crose LE, Etheridge KT, Chen C, Belyea B, Talbot LJ, Bentley RC, Linardic CM.

Clin Cancer Res. 2012 Jul 15;18(14):3780-90. doi: 10.1158/1078-0432.CCR-10-3063. Epub 2012 May 30.

10.

A mouse model of rhabdomyosarcoma originating from the adipocyte lineage.

Hatley ME, Tang W, Garcia MR, Finkelstein D, Millay DP, Liu N, Graff J, Galindo RL, Olson EN.

Cancer Cell. 2012 Oct 16;22(4):536-46. doi: 10.1016/j.ccr.2012.09.004.

11.

NRASG12V oncogene facilitates self-renewal in a murine model of acute myelogenous leukemia.

Sachs Z, LaRue RS, Nguyen HT, Sachs K, Noble KE, Mohd Hassan NA, Diaz-Flores E, Rathe SK, Sarver AL, Bendall SC, Ha NA, Diers MD, Nolan GP, Shannon KM, Largaespada DA.

Blood. 2014 Nov 20;124(22):3274-83. doi: 10.1182/blood-2013-08-521708. Epub 2014 Oct 14.

12.

Dominant role of oncogene dosage and absence of tumor suppressor activity in Nras-driven hematopoietic transformation.

Xu J, Haigis KM, Firestone AJ, McNerney ME, Li Q, Davis E, Chen SC, Nakitandwe J, Downing J, Jacks T, Le Beau MM, Shannon K.

Cancer Discov. 2013 Sep;3(9):993-1001. doi: 10.1158/2159-8290.CD-13-0096. Epub 2013 Jun 3.

13.

MIG6 Is MEK Regulated and Affects EGF-Induced Migration in Mutant NRAS Melanoma.

Vu HL, Rosenbaum S, Capparelli C, Purwin TJ, Davies MA, Berger AC, Aplin AE.

J Invest Dermatol. 2016 Feb;136(2):453-63. doi: 10.1016/j.jid.2015.11.012. Epub 2015 Nov 20.

14.

The Hippo transducer YAP1 transforms activated satellite cells and is a potent effector of embryonal rhabdomyosarcoma formation.

Tremblay AM, Missiaglia E, Galli GG, Hettmer S, Urcia R, Carrara M, Judson RN, Thway K, Nadal G, Selfe JL, Murray G, Calogero RA, De Bari C, Zammit PS, Delorenzi M, Wagers AJ, Shipley J, Wackerhage H, Camargo FD.

Cancer Cell. 2014 Aug 11;26(2):273-87. doi: 10.1016/j.ccr.2014.05.029. Epub 2014 Jul 31.

16.

Lin28b promotes head and neck cancer progression via modulation of the insulin-like growth factor survival pathway.

Alajez NM, Shi W, Wong D, Lenarduzzi M, Waldron J, Weinreb I, Liu FF.

Oncotarget. 2012 Dec;3(12):1641-52.

17.

Preclinical efficacy of MEK inhibition in Nras-mutant AML.

Burgess MR, Hwang E, Firestone AJ, Huang T, Xu J, Zuber J, Bohin N, Wen T, Kogan SC, Haigis KM, Sampath D, Lowe S, Shannon K, Li Q.

Blood. 2014 Dec 18;124(26):3947-55. doi: 10.1182/blood-2014-05-574582. Epub 2014 Oct 31.

18.

Downregulation of HMGA2 by the pan-deacetylase inhibitor panobinostat is dependent on hsa-let-7b expression in liver cancer cell lines.

Di Fazio P, Montalbano R, Neureiter D, Alinger B, Schmidt A, Merkel AL, Quint K, Ocker M.

Exp Cell Res. 2012 Sep 10;318(15):1832-43. doi: 10.1016/j.yexcr.2012.04.018. Epub 2012 Jun 8.

PMID:
22683924
19.

RKIP and HMGA2 regulate breast tumor survival and metastasis through lysyl oxidase and syndecan-2.

Sun M, Gomes S, Chen P, Frankenberger CA, Sankarasharma D, Chung CH, Chada KK, Rosner MR.

Oncogene. 2014 Jul 3;33(27):3528-37. doi: 10.1038/onc.2013.328. Epub 2013 Aug 26.

20.

Hmga2 is required for canonical WNT signaling during lung development.

Singh I, Mehta A, Contreras A, Boettger T, Carraro G, Wheeler M, Cabrera-Fuentes HA, Bellusci S, Seeger W, Braun T, Barreto G.

BMC Biol. 2014 Mar 24;12:21. doi: 10.1186/1741-7007-12-21.

Supplemental Content

Support Center